PLN 75068
Alternative Names: PLN-75068Latest Information Update: 28 Sep 2024
At a glance
- Originator Pliant Therapeutics
- Class Anti-inflammatories; Antifibrotics; Small molecules
- Mechanism of Action Integrin alphavbeta1 inhibitors; Integrin alphaVbeta6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Idiopathic pulmonary fibrosis
- No development reported Primary biliary cirrhosis; Primary sclerosing cholangitis
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in Primary-biliary-cirrhosis in USA (PO)
- 28 Jun 2023 No recent reports of development identified for preclinical development in Primary-sclerosing-cholangitis in USA (PO)
- 19 May 2023 Preclinical trials in Idiopathic pulmonary fibrosis in USA (PO), prior to May 2023